drugset / Trial / NCT05849311
Phase I Trial of Envafolimab for Healthy Male Subjects
RandomizedParallel-groupQuadruple-blindOther
Summary
The purpose of this study is to evaluate the pharmacokinetic similarity, safety, and immunogenicity of Envafolimab in healthy male subjects before and after the manufacturing process change.
Timeline
- Start
- 2023-05-29
- Primary completion
- 2023-11-15
- Completion
- 2023-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Envafolimab | Monoclonal antibody | 1 mg/kg | Subcutaneous |
Indications
No indication recorded.